Biochemical characterization of Rift Valley fever virus

Rice, Robert M.; Erlick, Barry J.; Rosato, Robert R.; Eddy, Gerald A.; Mohanty, S. B.

doi:10.1016/0042-6822(80)90175-0

Cited by 23 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The question was raised of whether the 78 kDa protein is a structural protein [227], but a more recent work indicated that this protein was not detected in purified particles [89]. The NSm1 and NSm2 nonstructural proteins are produced by alternative use of the first or the second of the 5 in-frame AUG codons present at the 5′ end of the M mRNA and located upstream of the G n sequence (Fig.…”

Section: Genetic Organization Of the Rvfvmentioning

confidence: 99%

Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention

et al. 2010

View full text Add to dashboard Cite

Rift Valley fever (RVF) virus is an arbovirus in the Bunyaviridae family that, from phylogenetic analysis, appears to have first emerged in the mid-19th century and was only identified at the begininning of the 1930s in the Rift Valley region of Kenya. Despite being an arbovirus with a relatively simple but temporally and geographically stable genome, this zoonotic virus has already demonstrated a real capacity for emerging in new territories, as exemplified by the outbreaks in Egypt (1977), Western Africa (1988) and the Arabian Peninsula (2000), or for re-emerging after long periods of silence as observed very recently in Kenya and South Africa. The presence of competent vectors in countries previously free of RVF, the high viral titres in viraemic animals and the global changes in climate, travel and trade all contribute to make this virus a threat that must not be neglected as the consequences of RVF are dramatic, both for human and animal health. In this review, we present the latest advances in RVF virus research. In spite of this renewed interest, aspects of the epidemiology of RVF virus are still not fully understood and safe, effective vaccines are still not freely available for protecting humans and livestock against the dramatic consequences of this virus.

show abstract

Section: Genetic Organization Of the Rvfvmentioning

confidence: 99%

Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Although a protein product has not been clearly defined from all in-frame methionine residues [140], all five remain conserved among 33 ecologically diverse RVFV strains [133]. The mature, glycosylated Gn (56 kDa) and Gc (65 kDa) proteins [126,141] are essential for several steps in the virus lifecycle such as receptor recognition, entry, and budding [54,142], whereas the NSm proteins are dispensable for viral replication in cell culture [143,144].…”

Section: Segmentmentioning

confidence: 99%

Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus

et al. 2009

View full text Add to dashboard Cite

Rift Valley Fever virus (RVFV) regularly accounts for severe and often lethal outbreaks among livestock and humans in Africa. Safe and effective veterinarian and human vaccines are highly needed. We present evidence that administration of RVF virus-like particles (VLPs) induces protective immunity in mice. In an accompanying paper, (Habjan, M., Penski, N., Wagner, V., Spiegel, M., Overby, A.K., Kochs, G., Huiskonen, J., Weber, F., 2009. Efficient production of Rift Valley fever virus-like particles: the antiviral protein MxA can inhibit primary transcription of Bunyaviruses. Virology 385, 400-408) we report the production of these VLPs in mammalian cells. After three subsequent immunizations with 1x10(6) VLPs/dose, high titers of virus-neutralizing antibodies were detected; 11 out of 12 mice were protected from challenge and only 1 out of 12 mice survived infection in the control groups. VLP vaccination efficiently suppressed replication of the challenge virus, whereas in the control animals high RNA levels and increasing antibody titers against the nucleocapsid protein indicated extensive viral replication. Our study demonstrates that the RVF VLPs are highly immunogenic and confer protection against RVFV infection in mice. In the test groups, the vaccinated mice did not exhibit any side effects, and the lack of anti-nucleocapsid protein antibodies serologically distinguished vaccinated animals from experimentally infected animals.

show abstract

“…wt. of 25 × 103 (Rice et al, 1980). Information on replication of the virus is limited and nonstructural proteins are unknown (Bishop et al, 1980).…”

Section: Discussionmentioning

confidence: 99%

Identification of a Major Non-structural Protein in the Nuclei of Rift Valley Fever Virus-infected Cells

Struthers

Swanepoel

1982

Journal of General Virology

View full text Add to dashboard Cite

Biochemical characterization of Rift Valley fever virus

Cited by 23 publications

References 16 publications

Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention

Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention

Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus

Identification of a Major Non-structural Protein in the Nuclei of Rift Valley Fever Virus-infected Cells

Contact Info

Product

Resources

About